Tannic acid modified silver nanoparticles show antiviral activity in herpes simplex virus type 2 infection

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Orlowski, Piotr ^a   Tomaszewska, Emilia ^b   Gniadek, Marianna ^c   Baska, Piotr ^d   Nowakowska, Julita ^e   Sokolowska, Justyna ^d   Nowak, Zuzanna ^d   Donten, Mikolaj ^c   Celichowski, Grzegorz ^b   Grobelny, Jaroslaw ^b   Krzyzowska, Malgorzata ^a  

^a MILITARY INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

^c UNIVERSITY OF WARSAW   (Poland)

^d WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^e UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYTOKINE; METAL NANOPARTICLE; SILVER; TANNIN DERIVATIVE;

ANIMAL; CELL LINE; CHEMISTRY; CHLOROCEBUS AETHIOPS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; INFLAMMATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MOUSE; ULTRASTRUCTURE; VIROLOGY; VIRUS ATTACHMENT; VIRUS ENTRY;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HERPES SIMPLEX; HERPESVIRUS 2, HUMAN; INFLAMMATION; METAL NANOPARTICLES; MICE; MICROBIAL SENSITIVITY TESTS; SILVER; TANNINS; VIRUS ATTACHMENT; VIRUS INTERNALIZATION;

EID: 84905912336     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104113     Document Type: Article

References (65)

1. Shukla D, Spear PG (2001) Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J Clin Invest 108:503-510. (Pubitemid 32777727)
2. Garner JA (2003) Herpes simplex virion entry into and intracellular transport within mammalian cells. Adv Drug Deliv Rev 55:1497-1513.
3. Akhtar J, Shukla D (2009) Viral entry mechanism: cellular and viral mediators of herpes simplex virus entry. FEBS J 276: 7228-7236.
4. Gupta R, Warren T, Wald A (2007) Genital herpes. Lancet 370: 2127-2137. (Pubitemid 350296304)
5. Halioua B, Malkin JE (1999) Epidemiology of genital herpes - recent advances. Eur J Dermatol 9: 177-184. (Pubitemid 29170416)
6. Kahababaee K, van Ree T (2001) Tannins: classification and definition. Nat Prod Rep 18: 641-649.
7. Haslam E (2007) Vegetable tannins - lessons of a plant phytochemical lifetime. Phytochemistry 68: 2713-2721.
8. Athar M, Khan WA, Mukhtar H (1989) Effect of dietary tannic acid on epidermal, lung, and forestomach polycyclic aromatic hydrocarbon metabolism and tumorigenicity in Sencar mice. Cancer Res 49: 5784-5788. (Pubitemid 19274124)
9. Horikawa K, Mohri T, Tanaka Y, Tokiwa H (1994) Moderate inhibition of mutagenicity and carcinogenicity of benzo[a]pyrene, 1,6-dinitropyrene and 3,9-dinitrofluoranthene by Chinese medicinal herbs. Mutagenesis 9: 523-526. (Pubitemid 24354773)
10. Chung KT, Stevens SE Jr, Lin WF, Wei CI (1993) Growth inhibition of selected food-borne bacteria by tannic acid, propyl gallate and related compounds. Appl Microbiol 1: 29-32.
11. Fukuchi K, Sakagami H, Okuda T, Hatano T, Tanuma S, et al. (1989) Inhibition of herpes simplex virus infection by tannins and related compounds. Antiviral Res 11: 285-298. (Pubitemid 19182401)
12. Scalbert A (1989) Antimicrobial properties of tannins. Phytochemistry 30: 3875-3883.
13. Akiyama H, Fujii K, Yamasaki O, Oono T, Iwatsuki K (2001) Antibacterial action of several tannins against Staphylococcus aureus. J Antimicrob Chemother 48: 487-491. (Pubitemid 33040688)
14. Nelofer SK, Ahmad A, Hadi SM (2000) Anti-oxidant, pro-oxidant properties of tannic acid and its binding to DNA. Chem Biol Interact 125: 177-189. (Pubitemid 30145627)
15. Lin LT, Chen TY, Chung CY, Noyce RS, Gridley TB, et al. (2011) Hydrolyzable tannins (chebulagic acid and punicalagin) target viral glycoprotein glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry and cell-to-cell spread. J Virol 85: 4386-4398.
16. Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, et al. (2005) The bactericidal effect of silver nanoparticles. Nanotechnology 16: 2346-2353. (Pubitemid 41376178)
17. Kim JS, Kuk E, Yu KN, Kim JH, Park SJ, et al. (2007) Antimicrobial effects of silver nanoparticles. Nanomedicine 3: 95-101. (Pubitemid 46428190)
18. Kim KJ, Sung WS, Moon SK, Choi JS, Kim JG, et al. (2008) Antifungal effect of silver nanoparticles on dermatophytes. J Microbiol Biotechnol 18: 148-1484.
19. Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, et al. (2005) Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology 3: 6.
20. Lara HH, Ayala-Nunez NV, Ixtepan-Turrent L, Rodriguez-Padilla C (2010) Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology 8:1.
21. Lu L, Sun RW, Chen R, Hui CK, Ho CM, et al. (2008) Silver nanoparticles inhibit hepatitis B virus replication. Antivir Ther 13: 253-262.
22. Xiang D, Zheng Y, Duan W, Li X, Yin J, et al. (2013) Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo. Int J Nanomedicine 8: 4103-4114.
23. Baram-Pinto D, Shukla S, Perkas N, Gedanken A, Sarid R (2009) Inhibition of herpes simplex virus type 1 infection by silver nanoparticles capped with mercaptoethanesulfonate. Bioconjug Chem 19: 1497-1502.
24. Kleymann G (2005) Agents and strategies in development for improved management of herpes simplex virus infection and disease. Expert Opin Investig Drugs 14: 135-161.
25. Piret J, Boivin G (2011) Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 55: 459-472.
26. Levin MJ, Bacon TH, Leary JJ (2004) Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 39: 248-257.
27. Wade JC (2006) Viral infections in patients with hematological malignancies. Hematology Am Soc Hematol Educ Program 2006: 368-374.
28. Tobian AA, Quinn TC (2009) Herpes simplex virus type 2 and syphilis infections with HIV: an evolving synergy in transmission and prevention. Curr Opin HIV AIDS 4: 294-299.
29. Orlowski P, Krzyzowska M, Zdanowski R, Winnicka A, Nowakowska J, et al. (2013) Assessment of in vitro cellular responses of monocytes and keratinocytes to tannic acid modified silver nanoparticles. Toxicol In vitro 27: 1798-1808.
30. Duff R, Rapp F (1971) Oncogenic transformation of hamster cells after exposure to herpes simplex virus type 2. Nat New Biol 233: 48-50.
31. Krzyzowska M, Shestakov A, Eriksson E, Chiodi F (2011) Role of Fas/FasL in regulation of inflammation in vaginal tissue during HSV-2 infection. Cell Death Dis 2: 1-12.
32. Gunalp A (1965) Growth and cytopathic effect of rubella virus in a line of green monkey kidney cells. Proc Soc Exp Biol Med 118: 185-190.
33. Kulesz-Martin M, Yoshida MA, Prestine L, Yuspa SH, Bertram JS (1985) Mouse cell clones for improved quantitation of carcinogen-induced altered differentiation. Carcinogenesis 6: 1245-1254. (Pubitemid 15013323)
34. Varghese M1, Gorsevski P, Cayer ML, Boudreau NS, Heckman CA (2012) Unraveling the determinants of protrusion formation. Int J Cell Biol 2012: 402916.
35. Namvar L, Olofsson S, Bergstrom T, Lindh M (2005) Detection and typing of herpes simplex virus (HSV) in mucocutaneous samples by TaqMan PCR targeting a gB segment homologous for HSV types 1 and 2. J Clin Microbiol 43: 2058-2064. (Pubitemid 40656208)
36. Parr MB, Kepple L, McDermott MR, Drew MD, Bozzola JJ, et al. (1994) A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab Invest 70: 369-380. (Pubitemid 24116531)
37. Krzyzowska M, Baska P, Grochowska A, Orlowski P, Nowak Z, et al. (2014) Fas/FasL pathway participates in resolution of mucosal inflammatory response early during HSV-2 infection. Immunobiology 219: 64-77.
38. Galvin SR, Cohen MS (2004) The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2: 33-42. (Pubitemid 39490046)
39. Mohammed Fayaz A, Ao Z, Girilal M, Chen L, Xiao X, et al. (2012) Inactivation of microbial infectiousness by silver nanoparticles-coated condom: a new approach to inhibit HIV- and HSV-transmitted infection. Int J Nanomedicine 7: 5007-5018.
40. Lara HH, Ixtepan-Turrent L, Garza-Treviño EN, Rodriguez-Padilla C (2010) PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture. J Nanobiotechnology 8: 15.
41. Baram-Pinto D, Shukla S, Gedanken A, Sarid R (2010) Inhibition of HSV-1 attachment, entry, and cell-to-cell spread by functionalized multivalent gold nanoparticles. Small 6: 1044-1050.
42. Lin LT1, Chen TY, Lin SC, Chung CY, Lin TC, et al. (2013) Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. BMC Microbiol 13: 187.
43. de Lima R, Seabra AB, Durán N (2012) Silver nanoparticles: a brief review of cytotoxicity and genotoxicity of chemically and biogenically synthesized nanoparticles. J Appl Toxicol 32: 867-879.
44. Grünewald K, Desai P, Winkler DC, Heymann JB, Belnap DM, et al. (2003) Three-dimensional structure of herpes simplex virus from cryo-electron tomography. Science 302: 1396-1398. (Pubitemid 37452181)
45. Trefry JC, Wooley DP (2013) Silver nanoparticles inhibit vaccinia virus infection by preventing viral entry through a macropinocytosis-dependent mechanism. J Biomed Nanotechnol 9: 1624-1635.
46. Gaikwad S, Ingle A, Gade A, Rai M, Falanga A, et al. (2013) Antiviral activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza virus type 3. Int J Nanomedicine 8: 4303-4314.
47. Pal S, Tak YK, Song JM (2007) Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the Gram-negative bacterium Escherichia coli. Appl Environ Microbiol 73:1712-1720. (Pubitemid 46449051)
48. Yen HJ, Hsu SH, Tsai CL (2009) Cytotoxicity and immunological response of gold and silver nanoparticles of different sizes. Small 5: 1553-1561.
49. Johnston HJ, Hutchison G, Christensen FM, Peters S, Hankin S, et al. (2010) A review of the in vivo and in vitro toxicity of silver and gold particulates: particle attributes and biological mechanisms responsible for the observed toxicity. Crit Rev Toxicol 40: 328-346.
50. Liu W, Wu Y, Wang C, Li HC, Wang T, et al. (2010) Impact of silver nanoparticles on human cells: effect of particle size. Nanotoxicology 4: 319-330.
51. Samberg ME, Oldenburg SJ, Monteiro-Riviere NA (2010) Evaluation of silver nanoparticle toxicity in skin in vivo and keratinocytes in vitro. Environ Health Perspect 118: 407-413.
52. Milligan GN (1999) Neutrophils aid in protection of the vaginal mucosae of immune mice against challenge with herpes simplex virus type 2. J Virol 73: 6380-6386.
53. Wong KK, Cheung SO, Huang L, Niu J, Tao C, et al. (2009) Further evidence of the anti-inflammatory effects of silver nanoparticles. Chem Med Chem 4: 1129-1135.
54. Yilma AN, Singh SR Dixit S, Dennis VA (2013) Anti-inflammatory effects of silver-polyvinyl pyrrolidone (Ag-PVP) nanoparticles in mouse macrophages infected with live Chlamydia trachomatis. Int J Nanomedicine 8: 2421-2432.
55. Liu H, Yang D, Yang H, Zhang H, Zhang W, et al. (2013) Comparative study of respiratory tract immune toxicity induced by three sterilisation nanoparticles: Silver, zinc oxide and titanium dioxide. J Hazard Mater 248-249: 478-486.
56. Cumberbatch M, Dearman RJ, Kimber I (1997) Langerhans cells require signals from both tumour necrosis factor alpha and interleukin 1 beta for migration. Adv Exp Med Biol 92: 125-128.
57. Aoki R, Kawamura T, Goshima F, Ogawa Y, Nakae S, et al. (2013). Mast cells play a key role in host defense against herpes simplex virus infection through TNF-α and IL-6 production. J Invest Dermatol 133: 2170-2179.
58. Iijima N, Mattei LM, Iwasaki A (2011) Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissue. Proc Natl Acad Sci U S A 108: 284-289.
59. Thapa M, Carr DJ (2008) Chemokines and chemokine receptors critical to host resistance following genital herpes simplex virus type 2 (HSV-2) infection. Open Immunol J 1: 33-41.
60. Mahad D, Callahan MK, Williams KA, Ubogu EE, Kivisakk P, et al. (2005) Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 129: 212-223.
61. Campbell SJ, Perry VH, Pitossi FJ, Butchart AG, Chertoff M, et al. (2005) Central nervous system injury triggers hepatic CC and CXC chemokine expression that is associated with leukocyte mobilization and recruitment to both the central nervous system and the liver. Am J Pathol 166: 1487-1497. (Pubitemid 40586518)
62. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, et al. (1994) Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339-342. (Pubitemid 24104268)
63. Paludan SR (2001) Requirements for the induction of interleukin-6 by herpes simplex virus-infected leukocytes. J Virol 75: 8008-8015.
64. Nakanishi Y, Lu B, Gerard C, Iwasaki A (2009) CD8 (+) T lymphocyte mobilization to virus-infected tissue requires CD4 (+) T-cell help. Nature 462: 510-513.
65. Lund JM, Hsing L, Pham TT, Rudensky AY (2008) Coordination of early protective immunity to viral infection by regulatory T cells. Science 320: 1220-1224. (Pubitemid 351929511)